Amendment: Outcomes of Transplantation in Acute Lymphoblastic Leukemia with Philadelphia Chromosome and Additional Cytogenetic Abnormalities: Research by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

By
Arnon Nagler
Jordi Esteve
Jacques-Emmanuel Galimard
Depei Wu
Erlie Jiang
Nathalie Dhedin
Anne Sirvent
Jan Vydra
Jakob Passweg
Bruno Lioure
Jaime Sanz
Jurjen Versluis
Yajing Xu
Cristina Castilla-Llorente
Rodrigo Martino Bufarull
Victoria Potter
Nour Ben Abdeljelil
Eolia Brissot
Ali Bazarbachi
Bipin Savani
Sebastian Giebel
Mohamad Mohty
Fabio Ciceri
August 31, 2026

Bone Marrow Transplantation

Background

Acute lymphoblastic leukemia (ALL) is a hematological malignancy that can be complicated by the presence of the Philadelphia chromosome and additional cytogenetic abnormalities. Understanding the impact of these abnormalities on transplantation outcomes is crucial for optimizing treatment strategies. The European Society for Blood and Marrow Transplantation (EBMT) provides guidelines for the management of Ph+ ALL.

Data Highlights

No numerical data is provided in the source material.

Key Findings

The study was conducted on behalf of the Acute Leukemia Working Party of the EBMT.
Correction made to the title of the original article to reflect the study's affiliation.
No significant differences in overall survival, leukemia-free survival, relapse incidence, or non-relapse mortality were found between patients with and without additional cytogenetic abnormalities.
MRD negativity prior to HCT was more frequent among patients with additional cytogenetic abnormalities.

Clinical Implications

The findings suggest that the presence of additional cytogenetic abnormalities in Ph+ ALL patients does not negatively impact transplantation outcomes. This information may assist clinicians in making informed decisions regarding allo-HCT for these patients.

Conclusion

The correction to the study title clarifies the research's affiliation and that additional cytogenetic abnormalities do not adversely affect transplantation outcomes in Ph+ ALL patients in the TKI era.